ATE225178T1 - Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände - Google Patents

Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände

Info

Publication number
ATE225178T1
ATE225178T1 AT97928369T AT97928369T ATE225178T1 AT E225178 T1 ATE225178 T1 AT E225178T1 AT 97928369 T AT97928369 T AT 97928369T AT 97928369 T AT97928369 T AT 97928369T AT E225178 T1 ATE225178 T1 AT E225178T1
Authority
AT
Austria
Prior art keywords
chelates
treatment
free radicals
conditions caused
metal
Prior art date
Application number
AT97928369T
Other languages
German (de)
English (en)
Inventor
Jan Olof Gustav Karlsson
Per Jynge
Robertson Towart
Original Assignee
Amersham Health As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Health As filed Critical Amersham Health As
Application granted granted Critical
Publication of ATE225178T1 publication Critical patent/ATE225178T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/32Manganese; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Manufacture And Refinement Of Metals (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Semiconductor Lasers (AREA)
AT97928369T 1996-06-24 1997-06-24 Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände ATE225178T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613182.6A GB9613182D0 (en) 1996-06-24 1996-06-24 Method
PCT/GB1997/001722 WO1997049409A1 (en) 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radicals induced conditions

Publications (1)

Publication Number Publication Date
ATE225178T1 true ATE225178T1 (de) 2002-10-15

Family

ID=10795775

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97928369T ATE225178T1 (de) 1996-06-24 1997-06-24 Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände
AT97928368T ATE228361T1 (de) 1996-06-24 1997-06-24 Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97928368T ATE228361T1 (de) 1996-06-24 1997-06-24 Reduzierung der kardiotoxizität von antitumormitteln mit manganverbindungen

Country Status (14)

Country Link
US (2) US6147094A (index.php)
EP (2) EP0910360B1 (index.php)
JP (2) JP4162263B2 (index.php)
CN (2) CN1228703A (index.php)
AT (2) ATE225178T1 (index.php)
AU (2) AU720621B2 (index.php)
BR (1) BR9709942A (index.php)
CA (2) CA2258299A1 (index.php)
DE (2) DE69717447T2 (index.php)
GB (1) GB9613182D0 (index.php)
IL (1) IL127733A0 (index.php)
NO (2) NO985916L (index.php)
NZ (2) NZ333357A (index.php)
WO (2) WO1997049390A1 (index.php)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
EP1060174B1 (en) * 1997-12-23 2004-09-22 Amersham Health AS Nitric oxide releasing chelating agents and their therapeutic use
CN1390231A (zh) 1999-10-01 2003-01-08 Dmi生物科学公司 金属-结合性化合物及其用途
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
US8022279B2 (en) 2004-04-22 2011-09-20 Celator Pharmaceuticals, Inc. Liposomal formulations of anthracycline agents and cytidine analogs
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
CA2708113C (en) * 2007-12-14 2017-08-22 Pledpharma Ab Compounds for use in the treatment of cancer
MX336359B (es) * 2009-07-06 2016-01-15 Pledpharma Ab Composiciones farmaceuticas y metodos teraputicos que emplean una combinacion de un compuesto complejo de manganeso y una forma compleja no de manganeso del compuesto.
HRP20200793T1 (hr) 2011-05-09 2020-10-16 Mayo Foundation For Medical Education And Research Liječenje raka
IN2014MN01495A (index.php) * 2012-01-05 2015-04-17 Pledpharma Ab
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
US20150313921A1 (en) 2012-11-02 2015-11-05 Pledpharma Ab Cancer Treatment Methods
US20160250351A1 (en) 2014-06-13 2016-09-01 Mayo Foundation For Medical Education And Research Treating Lymphomas
JP6600651B2 (ja) 2014-06-16 2019-10-30 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 骨髄腫の治療
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017165440A1 (en) * 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
CA3018340A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN109890419A (zh) 2016-09-01 2019-06-14 梅约医学教育与研究基金会 用于治疗癌症的载体-pd-l1结合剂组合物
RU2019109209A (ru) 2016-09-01 2020-10-05 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Способ и композиции для направленного на мишень воздействия при лечении т-клеточных видов рака
KR20230010817A (ko) 2016-09-06 2023-01-19 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법
JP2019526587A (ja) 2016-09-06 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチMayo Foundation For Medical Education And Research Pd−l1を発現する癌を処置する方法
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444380A1 (es) * 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US5223243A (en) * 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Also Published As

Publication number Publication date
AU720570B2 (en) 2000-06-08
WO1997049409A1 (en) 1997-12-31
NZ333315A (en) 2000-07-28
CA2258299A1 (en) 1997-12-31
WO1997049390A1 (en) 1997-12-31
NO985917L (no) 1999-01-25
ATE228361T1 (de) 2002-12-15
US6258828B1 (en) 2001-07-10
GB9613182D0 (en) 1996-08-28
DE69716104D1 (de) 2002-11-07
EP0936915A1 (en) 1999-08-25
NO985916D0 (no) 1998-12-17
JP2000514044A (ja) 2000-10-24
DE69717447T2 (de) 2003-09-11
AU720621B2 (en) 2000-06-08
IL127733A0 (en) 1999-10-28
BR9709942A (pt) 1999-08-10
US6147094A (en) 2000-11-14
NO985917D0 (no) 1998-12-17
EP0910360A1 (en) 1999-04-28
CN1228703A (zh) 1999-09-15
EP0910360B1 (en) 2002-11-27
NZ333357A (en) 2000-08-25
AU3268897A (en) 1998-01-14
NO985916L (no) 1999-01-25
JP4359651B2 (ja) 2009-11-04
EP0936915B1 (en) 2002-10-02
JP4162263B2 (ja) 2008-10-08
DE69717447D1 (de) 2003-01-09
DE69716104T2 (de) 2003-05-28
CA2259150A1 (en) 1997-12-31
AU3268997A (en) 1998-01-14
CN1228694A (zh) 1999-09-15
JP2000513351A (ja) 2000-10-10

Similar Documents

Publication Publication Date Title
ATE225178T1 (de) Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände
ATE277038T1 (de) Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
DE69703294D1 (de) Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
DE69942680D1 (de) Verfahren und Zusammensetzungen zur Prävention und Behandlung von Anämie
DE60121440D1 (de) Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DE69834658D1 (de) Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität
MXPA04000222A (es) Combinaciones para el tratamiento de desordenes inflamatorios.
DE69934590D1 (de) Verbindung und verfahren zur bekämpfung und/oder behandlung der allergie
ATE221781T1 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
DE69837324D1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
DE602004031356D1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
DE69413829D1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
DE69938036D1 (de) Mittel und verfahren zum schutz, zur behandlung und zur reparatur von bindegewebe
ATE485818T1 (de) Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
ATE273702T1 (de) Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon
EP1706452A4 (en) AROMATIC TRIAMIDE LANTHANIDE COMPLEXES
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60130659D1 (de) Therapeutische verbindungen und verfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties